MedDataX Logo

Effect of Brimonidine on Corneal Thickness

NCT ID: NCT01250236

Last Updated: 2010-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-12-31

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Brimonidine, an alpha-2 adrenoceptor agonist, is an effective and safe medication which is widely used in glaucoma treatment. Although it is known that it is quickly taken up by the cornea following topical administration and that the cornea has alpha-2 adrenoceptors there are only few studies available on the impact brimonidine has on the cornea. The aim of the study is to find out

1. whether topical administration of brimonidine results in interaction with corneal alpha-2 adrenoceptors in terms of an increase in corneal thickness and
2. whether there are any differences between the response corneal epithelium, stroma and endothelium show to alpha-2 adrenoceptor stimulation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Impact of Brimonidine on the Cornea

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

brimonidine alpha-2 adrenoceptor cornea corneal thickness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

verum

brimonidine 0.1% eye drops twice daily

brimonidine 0.1%

Intervention Type DRUG

brimonidine 0.1% eye drops twice daily

placebo

sodium hyaluronate 1.8mg/ml eye drops twice daily

placebo

Intervention Type DRUG

sodium hyaluronate 1.8mg/ml eye drops twice daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

brimonidine 0.1%

brimonidine 0.1% eye drops twice daily

Intervention Type DRUG

placebo

sodium hyaluronate 1.8mg/ml eye drops twice daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy, 18-99 years, normal ophthalmologic history, consent to participate in the study

Exclusion Criteria

* any serious medical or neurologic conditions and/or regular use of local or systemic medications
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Augenarztpraxis Breisach

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Augenarztpraxis Breisach

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Matthias Grueb, Priv. Doz. Dr.

Role: STUDY_DIRECTOR

Augenarztpraxis Breisach

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Augenarztpraxis

Breisach, Baden-Wurttemberg, Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Matthias Grueb, Priv. Doz. Dr.

Role: CONTACT

Phone: 004976677766

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Matthias Grueb, Priv. Doz. Dr.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Grueb Klin CT

Identifier Type: -

Identifier Source: org_study_id